Phaseline

Companies › Life Biosciences

Life Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ER-100
AAV-based epigenetic therapy delivering OSK transcription factors (OCT4, SOX2, KLF4) via i
OCT4, SOX2, KLF4Phase 1Open Angle Glaucoma (OAG)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07290244ER-100Phase 1Open Angle Glaucoma (OAG)OphthalmologyMay 2027

Targets

OCT4 (1) SOX2 (1) KLF4 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.